Elvanse® (Lisdexamfetamine Dimesylate) Receives UK Marketing Authorisation - New Option For The Treatment Of ADHD In Children And Adolescents
Shire plc (LSE: SHP, NASDAQ: SHPG) have announced that its single-daily dose long-acting prodrug stimulant, Elvanse, has been authorised by the MHRA for the treatment of ADHD in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.2 Elvanse is the first stimulant prodrug to be launched in Europe for the treatment of ADHD. It is ingested in an inactive form and subsequently activated within the body, meaning that the active part of Elvanse is gradually released over time... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 13, 2013 Category: Consumer Health News Tags: ADHD Source Type: news
Trends in office-based treatment of adults with stimulants in the United States
Source: Journal of Clinical Psychiatry
Area: Evidence > Medicines Management > References
Objective: The authors investigated trends and patterns in stimulant treatment of adults visiting office-based medical practices in the United States.
Method: A time series analysis of data from the 1994 to 2009 National Ambulatory Medical Care Surveys (no of visits = 372,702) was performed, focusing on adult (aged 18 years or older) visits in which stimulant medications (amphetamine salts, methylphenidate or pemoline) were prescribed. The authors computed trends in the percentage of visits in which a stimulant w...
Source: NeLM - Mental Health - January 25, 2013 Category: Psychiatry Source Type: news
Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial
Source: BMC Psychiatry
Area: Evidence > Medicines Management > References
Background: Medication non-adherence has an important impact on treatment efficacy and healthcare burden across a range of conditions and therapeutic areas. The aim of this analysis was to determine predictors of non-adherence and impact of non-adherence on treatment response in adults with attention-deficit/hyperactivity disorder (ADHD).
Methods: Post-hoc analysis of a 13-week, randomised, double-blind, placebo-controlled study of OROS methylphenidate (MPH) 54 and 72 mg/day at 42 sites in 11 European countries including th...
Source: NeLM - Mental Health - January 25, 2013 Category: Psychiatry Source Type: news
Postpartum Depression Looks Almost Like Psychosis
Postpartum thyroid disturbances or severe abnormalities of the hypothalamus can look like depression or psychosis, but can also be medical emergencies. Hormonal changes during and after pregnancy are very significant and enough to wreak havoc on one’s mental state. I encourage child-bearing women to discuss any mood disturbances with their physicians and their partner. read more (Source: Psychology Today Depression Center)
Source: Psychology Today Depression Center - January 15, 2013 Category: Psychiatry & Psychology Authors: Robert J. Hedaya, M.D., D.F.A.P.A Tags: Depression Health Parenting Sex bloating Cymbalta dry skin early meetings hormonal changes hypothalamus lamictal low energy medical emergencies medication trials methylphenidate monoamine oxidase inhibitor mood disturbances Source Type: news
Pfizer Announces Availability Of Quillivant XR (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States
The First Once-Daily, Extended-Release Liquid Medication
for the Treatment of ADHD is Now Available in
Pharmacies
NEW YORK--(BUSINESS WIRE)--Jan 14, 2013 - Pfizer Inc. (NYSE:
PFE) today announced that Quillivant XR™... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2013 Category: Pharmaceuticals Source Type: news
